Double-edged roles of protein tyrosine phosphatase SHP2 in cancer and its inhibitors in clinical trials

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

The phosphoinositide 3-kinase pathway

Cantley, L. C. (2002) · Science · doi:10.1126/science.296.5573.1655 · Cited by 5,621 · see citing works

Protein kinases and phosphatases: The Yin and Yang of protein phosphorylation and signaling

Hunter, T. R. (1995) · Cell · doi:10.1016/0092-8674(95)90405-0 · Cited by 2,959 · see citing works

Phosphatidylinositol-3-OH kinase direct target of Ras

Rodriguez-Viciana, P., Warne, P. H., Dhand, R., Vanhaesebroeck, B., Gout, I., Fry, M. J., Waterfield, M. D., & Downward, J. (1994) · Nature · doi:10.1038/370527a0 · Cited by 1,954 · see citing works

Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome

Tartaglia, M., Mehler, E. L., Goldberg, R. B., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,736 · see citing works

T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition

Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., et al. (2017) · Science · doi:10.1126/science.aaf1292 · Cited by 1,689 · see citing works

Immune checkpoint signaling and cancer immunotherapy

He, X., & Xu, C. (2020) · Cell Research · doi:10.1038/s41422-020-0343-4 · Cited by 1,384 · see citing works

Regulation of JAK–STAT signalling in the immune system

Shuai, K., & Liu, B. (2003) · Nature reviews. Immunology · doi:10.1038/nri1226 · Cited by 1,379 · see citing works

The crucial role of protein phosphorylation in cell signaling and its use as targeted therapy (Review)

Ardito, F., Giuliani, M., PERRONE, D., Troiano, G., & Muzio, L. L. (2017) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2017.3036 · Cited by 1,349 · see citing works

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., & Saito, T. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20112741 · Cited by 1,161 · see citing works

Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia

Tartaglia, M., Niemeyer, C. M., Fragale, A., Song, X., Buechner, J., Jung, A., Hählen, K., Hasle, H., Licht, J. D., & Gelb, B. D. (2003) · Nature Genetics · doi:10.1038/ng1156 · Cited by 1,033 · see citing works

Crystal Structure of the Tyrosine Phosphatase SHP-2

Hof, P., Pluskey, S., Dhe‐Paganon, S., Eck, M. J., & Shoelson, S. E. (1998) · Cell · doi:10.1016/s0092-8674(00)80938-1 · Cited by 996 · see citing works

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925 · see citing works

CD28 and CTLA-4 coreceptor expression and signal transduction

Rudd, C. E., Taylor, A., & Schneider, H. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00770.x · Cited by 898 · see citing works

PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ

Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791 · see citing works

Src protein–tyrosine kinase structure and regulation

Roskoski, R. J. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.09.171 · Cited by 596 · see citing works

Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway

Hanafusa, H., Torii, S., Yasunaga, T., & Nishida, E. (2002) · Nature Cell Biology · doi:10.1038/ncb867 · Cited by 566 · see citing works

Activating Mutations of the Noonan Syndrome-Associated <b> <i>SHP2/PTPN11</i> </b> Gene in Human Solid Tumors and Adult Acute Myelogenous Leukemia

Bentires-Alj, M., Paez, J. G., David, F. S., Keilhack, H., Halmos, B., Naoki, K., Maris, J. M., Richardson, A., Bardelli, A., Sugarbaker, D. J., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1923 · Cited by 509 · see citing works

Combinatorial control of the specificity of protein tyrosine phosphatases

Tonks, N. K., & Neel, B. G. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00196-4 · Cited by 496 · see citing works

Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment.

Zhang, S.-Q., Yang, W., Kontaridis, M. I., Bivona, T., Wen, G., Araki, T., Luo, J.-C., Thompson, J. A., Schraven, B., Philips, M., et al. (2004) · Molecules and Cells · doi:10.1016/s1097-2765(04)00050-4 · Cited by 470 · see citing works

Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis

Loh, M. L. (2003) · Blood · doi:10.1182/blood-2003-09-3287 · Cited by 425 · see citing works

RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1- and RAS-driven cancers

Nichols, R. J., Haderk, F., Stahlhut, C., Schulze, C. J., Hemmati, G., Wildes, D., Tzitzilonis, C., Mordec, K., Marquez, A., Romero, J., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0169-1 · Cited by 415 · see citing works

Protein-tyrosine-phosphatase SHPTP2 couples platelet-derived growth factor receptor beta to Ras.

Bennett, A. M., Tang, T. L., Sugimoto, S., Walsh, C. T., & Neel, B. G. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.15.7335 · Cited by 397 · see citing works

The tyrosine phosphatase Shp2 (PTPN11) in cancer

Chan, G., Kalaitzidis, D., & Neel, B. G. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9126-y · Cited by 383 · see citing works

PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase

Chan, R. J., & Feng, G. (2006) · Blood · doi:10.1182/blood-2006-07-028829 · Cited by 378 · see citing works

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase

Ruess, D. A., Heynen, G. J., Ciecielski, K. J., Ai, J., Berninger, A., Kabacaoglu, D., Görgülü, K., Dantes, Z., Wörmann, S. M., Diakopoulos, K. N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0024-8 · Cited by 370 · see citing works

The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway

Dance, M., Montagner, A., Salles, J.-P., Yart, A., & Raynal, P. (2008) · Cellular Signalling · doi:10.1016/j.cellsig.2007.10.002 · Cited by 361 · see citing works

A Novel Positive Feedback Loop Mediated by the Docking Protein Gab1 and Phosphatidylinositol 3-Kinase in Epidermal Growth Factor Receptor Signaling

Rodrigues, G. A., Falasca, M., Zhang, Z., Ong, S. H., & Schlessinger, J. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.4.1448-1459.2000 · Cited by 344 · see citing works

Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular Carcinogenesis

Bard-Chapeau, E. A., Li, S., Ding, J., Zhang, S. S., Zhu, H. H., Princen, F., Fang, D. D., Han, T., Bailly-Maitre, B., Poli, V., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.03.023 · Cited by 332 · see citing works

Form and Function in Protein Dephosphorylation

Denu, J. M., Stuckey, J. A., Saper, M. A., & Dixon, J. E. (1996) · Cell · doi:10.1016/s0092-8674(00)81356-2 · Cited by 330 · see citing works

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo

Mainardi, S., Mulero-Sánchez, A., Prahallad, A., Germano, G., Bosma, A., Krimpenfort, P., Lieftink, C., Steinberg, J. D., de Wit, N., Gonçalves-Ribeiro, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0023-9 · Cited by 320 · see citing works

Structural Analysis of Autoinhibition in the Ras Activator Son of Sevenless

Sondermann, H., Soisson, S. M., Boykevisch, S., Yang, S., Bar‐Sagi, D., & Kuriyan, J. (2004) · Cell · doi:10.1016/j.cell.2004.10.005 · Cited by 315 · see citing works

Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling

Agazie, Y. M., & Hayman, M. J. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.21.7875-7886.2003 · Cited by 306 · see citing works

Phosphorylation: Implications in Cancer

Singh, V., Ram, M., Kumar, R., Prasad, R., Roy, B., & Singh, K. (2017) · The Protein Journal · doi:10.1007/s10930-017-9696-z · Cited by 304 · see citing works

Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor

Garcia Fortanet, J., Chen, C. H.-T., Chen, Y.-N. P., Chen, Z., Deng, Z., Firestone, B., Fekkes, P., Fodor, M., Fortin, P. D., Fridrich, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00680 · Cited by 298 · see citing works

Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia

Tartaglia, M. (2004) · Blood · doi:10.1182/blood-2003-11-3876 · Cited by 291 · see citing works

Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3- and SHP2-mediated signals in immune responses.

Ohtani, T., Ishihara, K., Atsumi, T., Nishida, K., Kaneko, Y., Miyata, T., Itoh, S., Narimatsu, M., Maeda, H., Fukada, T., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)80162-4 · Cited by 284 · see citing works

Receptor-Specific Regulation of Phosphatidylinositol 3′-Kinase Activation by the Protein Tyrosine Phosphatase Shp2

Zhang, S. Q., Tsiaras, W. G., Araki, T., Wen, G., Minichiello, L., Klein, R., & Neel, B. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4062-4072.2002 · Cited by 283 · see citing works

Protein Kinases and Phosphatases in the Control of Cell Fate

Bononi, A., Agnoletto, C., Marchi, E. D., Marchi, S., Patergnani, S., Bonora, M., Giorgi, C., Missiroli, S., Poletti, F., Rimessi, A., et al. (2011) · Enzyme Research · doi:10.4061/2011/329098 · Cited by 283 · see citing works

The Tyrosine Phosphatase Shp2 in Development and Cancer

(2010) · Advances in Cancer Research · doi:10.1016/s0065-230x(10)06002-1 · Cited by 277 · see citing works

Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations

Mohi, G., Williams, I. R., Dearolf, C. R., Chan, G., Kutok, J. L., Cohen, S. L., Morgan, K. J., Boulton, C. L., Shigematsu, H., Keilhack, H., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.010 · Cited by 274 · see citing works

PTPN11 mutations in LEOPARD syndrome

Legius, E., Schrander-Stumpel, C. T. R. M., Schollen, E., Pulles‐Heintzberger, C. F. M., Gewillig, M. H. M. L., & Fryns, J.-P. (2002) · Journal of Medical Genetics · doi:10.1136/jmg.39.8.571 · Cited by 274 · see citing works

Molecular mechanism of SHP2 activation by PD-1 stimulation

Marasco, M., Berteotti, A., Weyershaeuser, J., Thorausch, N., Sikorska, J., Krausze, J., Brandt, H., Kirkpatrick, J., Ríos, P., Schamel, W. W. A., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay4458 · Cited by 268 · see citing works

Phase Separation of Disease-Associated SHP2 Mutants Underlies MAPK Hyperactivation

Zhu, G., Xie, J., Kong, W., Xie, J., Li, Y., Du, L., Zheng, Q., Sun, L., Guan, M., Li, H., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.002 · Cited by 267 · see citing works

An Shp2/SFK/Ras/Erk Signaling Pathway Controls Trophoblast Stem Cell Survival

Yang, W., Klaman, L. D., Chen, B., Araki, T., Harada, H., Thomas, S. Μ., George, E. L., & Neel, B. G. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.01.002 · Cited by 266 · see citing works

Visualization of intermediate and transition-state structures in protein-tyrosine phosphatase catalysis.

Denu, J. M., Lohse, D. L., Vijayalakshmi, J., Saper, M. A., & Dixon, J. E. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.6.2493 · Cited by 264 · see citing works

Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop

Aceto, N., Sausgruber, N., Brinkhaus, H., Gaidatzis, D., Martiny‐Baron, G., Mazzarol, G., Confalonieri, S., Quarto, M., Hu, G., Balwierz, P. J., et al. (2012) · Nature Medicine · doi:10.1038/nm.2645 · Cited by 263 · see citing works

Dissecting the catalytic mechanism of protein-tyrosinephosphatases.

Zhang, Z. Y., Wang, Y., & Dixon, J. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.5.1624 · Cited by 261 · see citing works

Tyrosine Phosphorylation of p85 Relieves Its Inhibitory Activity on Phosphatidylinositol 3-Kinase

Cuevas, B. D., Lu, Y., Mao, M., Zhang, J., LaPushin, R., Siminovitch, K. A., & Mills, G. B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m100556200 · Cited by 256 · see citing works

Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis

Bunda, S., Burrell, K., Heir, P., Zeng, L., Alamsahebpour, A., Kano, Y., Raught, B., Zhang, Z.-Y., Zadeh, G., & Ohh, M. (2015) · Nature Communications · doi:10.1038/ncomms9859 · Cited by 249 · see citing works

SHP2 sails from physiology to pathology

Tajan, M., de Rocca Serra, A., Valet, P., Edouard, T., & Yart, A. (2015) · European Journal of Medical Genetics · doi:10.1016/j.ejmg.2015.08.005 · Cited by 232 · see citing works

Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer

LaMarche, M. J., Acker, M., Argintaru, A., Bauer, D., Boisclair, J., Chan, H., Chen, C. H.-T., Chen, Y.-N., Chen, Z., Deng, Z., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01170 · Cited by 231 · see citing works

Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application

Yuan, X., Bu, H., Zhou, J., Yang, C., & Zhang, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00249 · Cited by 224 · see citing works

Correlation between PTPN11 gene mutations and congenital heart defects in Noonan and LEOPARD syndromes

Sárközy, A., Conti, E., Seripa, D., Digilio, M. C., Grifone, N., Tandoi, C., Fazio, V. M., Ciommo, V. M. D., Marino, B., Pizzuti, A., et al. (2003) · Journal of Medical Genetics · doi:10.1136/jmg.40.9.704 · Cited by 203 · see citing works

SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors

Dardaei, L., Wang, H. Q., Singh, M., Fordjour, P., Shaw, K. X., Yoda, S., Kerr, G., Yu, K., Liang, J., Cao, Y., et al. (2018) · Nature Medicine · doi:10.1038/nm.4497 · Cited by 199 · see citing works

Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation

Fragale, A., Tartaglia, M., Wu, J., & Gelb, B. D. (2004) · Human Mutation · doi:10.1002/humu.20005 · Cited by 193 · see citing works

Sodium Stibogluconate Is a Potent Inhibitor of Protein Tyrosine Phosphatases and Augments Cytokine Responses in Hemopoietic Cell Lines

Pathak, M. K., & Yi, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.6.3391 · Cited by 190 · see citing works

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade

Zhao, M., Guo, W., Wu, Y., Yang, C., Zhong, L., Deng, G., Zhu, Y., Liu, W., Gu, Y., Lu, Y., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.08.009 · Cited by 190 · see citing works

The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors

Wu, C.-J., O’Rourke, D. M., Feng, G., Johnson, G. R., Wang, Q., & Greene, M. I. (2001) · Oncogene · doi:10.1038/sj.onc.1204699 · Cited by 180 · see citing works

Targeting SHP2 as a promising strategy for cancer immunotherapy

Liu, Q., Qu, J., Zhao, M., Xu, Q., & Sun, Y. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104595 · Cited by 177 · see citing works

Discovery of SHP2-D26 as a First, Potent, and Effective PROTAC Degrader of SHP2 Protein

Wang, M., Lu, J., Wang, M., Yang, C.-Y., & Wang, S. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00471 · Cited by 172 · see citing works

Roles of Gab1 and SHP2 in Paxillin Tyrosine Dephosphorylation and Src Activation in Response to Epidermal Growth Factor

Ren, Y., Meng, S., Mei, L., Zhao, Z. J., Jove, R., & Wu, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312575200 · Cited by 171 · see citing works

The SHP-2 tyrosine phosphatase: Signaling mechanisms and biological functions

Qu, C. (2000) · Cell Research · doi:10.1038/sj.cr.7290055 · Cited by 167 · see citing works

Structural reorganization of SHP2 by oncogenic mutations and implications for oncoprotein resistance to allosteric inhibition

LaRochelle, J. R., Fodor, M., Vemulapalli, V., Mohseni, M., Wang, P., Stams, T., LaMarche, M. J., Chopra, R., Acker, M. G., & Blacklow, S. C. (2018) · Nature Communications · doi:10.1038/s41467-018-06823-9 · Cited by 167 · see citing works

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Liu, C., Lu, H., Wang, H., Loo, A., Zhang, X., Yang, G., Kowal, C., Delach, S., Wang, Y., Goldoni, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2718 · Cited by 167 · see citing works

Protein Tyrosine Phosphatases: Structure, Function, and Implication in Human Disease

Tautz, L., Critton, D., & Grotegut, S. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-562-0_13 · Cited by 164 · see citing works

The COOH-terminal Tyrosine Phosphorylation Sites on IRS-1 Bind SHP-2 and Negatively Regulate Insulin Signaling

Myers, M. G., Mendez, R., Shi, P., Pierce, J. H., Rhoads, R., & White, M. F. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.41.26908 · Cited by 164 · see citing works

Spectrum of mutations in PTPN11 and genotype–phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome

Musante, L., Kehl, H.-G., Majewski, F., Meinecke, P., Schweiger, S., Gillessen‐Kaesbach, G., Wieczorek, D., Hinkel, G. K., Tinschert, S., Hoeltzenbein, M., et al. (2003) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5200935 · Cited by 162 · see citing works

Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma

Tai, W., Cheng, A., Shiau, C., Huang, H., Huang, J., Chen, P., & Chen, K. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.01.047 · Cited by 158 · see citing works

Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor

Chan, R. J., Leedy, M. B., Munugalavadla, V., Voorhorst, C. S., Li, Y., Yu, M., & Kapur, R. (2005) · Blood · doi:10.1182/blood-2004-10-4002 · Cited by 156 · see citing works

Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy

Celis-Gutierrez, J., Blattmann, P., Zhai, Y., Jarmuzynski, N., Ruminski, K., Grégoire, C., Ounoughene, Y., Fiore, F., Aebersold, R., Roncagalli, R., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.041 · Cited by 154 · see citing works

Rel/NF-κB and IκB factors in oncogenesis

Luque, I., & Gélinas, C. (1997) · Seminars in Cancer Biology · doi:10.1006/scbi.1997.0061 · Cited by 145 · see citing works

Shp2 promotes liver cancer stem cell expansion by augmenting β‐catenin signaling and predicts chemotherapeutic response of patients

Xiang, D., Cheng, Z., Liu, H., Wang, X. B., Han, T., Sun, W. C., Li, X., Yang, W., Chen, C. Y., Xia, M., et al. (2016) · Hepatology · doi:10.1002/hep.28919 · Cited by 142 · see citing works

Structural and Mechanistic Insights into LEOPARD Syndrome-Associated SHP2 Mutations

Yu, Z.-H., Xu, J., Walls, C. D., Chen, L., Zhang, S., Zhang, R., Wu, L., Wang, L., Liu, S., & Zhang, Z. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.450023 · Cited by 141 · see citing works

PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients

Han, T., Xiang, D., Sun, W. C., Liu, N., Sun, H., Wen, W., Shen, W.-F., Wang, R., Chen, C. Y., Wang, X. B., et al. (2015) · Journal of Hepatology · doi:10.1016/j.jhep.2015.03.036 · Cited by 141 · see citing works

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Song, Z., Wang, M., Yang, G., Chen, X.-P., Xu, Z., Sun, Y., & Xiong, X. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.07.010 · Cited by 137 · see citing works

Modulation of the Nuclear Factor κb Pathway by Shp-2 Tyrosine Phosphatase in Mediating the Induction of Interleukin (Il)-6 by IL-1 or Tumor Necrosis Factor

You, M., Flick, L. M., Yu, D., & Feng, G. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.193.1.101 · Cited by 133 · see citing works

Dual Allosteric Inhibition of SHP2 Phosphatase

Fodor, M., Price, E. V., Wang, P., Lu, H., Argintaru, A., Chen, Z., Glick, M., Hao, H.-X., Kato, M., Koenig, R., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00980 · Cited by 133 · see citing works

Mechanism of activating mutations and allosteric drug inhibition of the phosphatase SHP2

Pádua, R. A. P., Sun, Y., Marko, I., Pitsawong, W., Stiller, J. B., Otten, R., & Kern, D. (2018) · Nature Communications · doi:10.1038/s41467-018-06814-w · Cited by 133 · see citing works

Helicobacter pylori CagA Phosphorylation Status Determines the gp130-activated SHP2/ERK and JAK/STAT Signal Transduction Pathways in Gastric Epithelial Cells

Lee, I. O., Kim, J., Choi, Y. J., Pillinger, M. H., Kim, S.-Y., Blaser, M. J., & Lee, Y. C. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.111054 · Cited by 132 · see citing works

The tyrosine phosphatase SHP2 controls TGFβ-induced STAT3 signaling to regulate fibroblast activation and fibrosis

Zehender, A., Huang, J., Györfi, A., Matei, A., Trinh‐Minh, T., Xu, X., Li, Y., Chen, C., Lin, J., Dees, C., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05768-3 · Cited by 129 · see citing works

Leukemogenic Ptpn11 causes fatal myeloproliferative disorder via cell-autonomous effects on multiple stages of hematopoiesis

Chan, G., Kalaitzidis, D., Usenko, T. S., Kutok, J. L., Yang, W., Mohi, G., & Neel, B. G. (2009) · Blood · doi:10.1182/blood-2008-10-182626 · Cited by 121 · see citing works

Mediating ERK1/2 signaling rescues congenital heart defects in a mouse model of Noonan syndrome

Nakamura, T., Colbert, M. C., Krenz, M., Molkentin, J. D., Hahn, H. S., Dorn, G. W., & Robbins, J. M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30756 · Cited by 120 · see citing works

mSprouty2 inhibits FGF10-activated MAP kinase by differentially binding to upstream target proteins

Tefft, D., Lee, M., Smith, S. M., Crowe, D. L., Bellusci, S., & Warburton, D. (2002) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00372.2001 · Cited by 118 · see citing works

Protein tyrosine phosphatase variants in human hereditary disorders and disease susceptibilities

Hendriks, W. J. A. J., & Pulido, R. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.05.022 · Cited by 113 · see citing works

Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment

Xie, J., Si, X., Gu, S., Wang, M., Shen, J. H., Li, H., Shen, J. H., Li, D., Fang, Y., Liu, C., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01520 · Cited by 113 · see citing works

Responses to Cytokines and Interferons that Depend upon JAKs and STATsPreprint

Stark, G. R., Cheon, H., & Wang, Y. (2017) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028555 · Cited by 111 · see citing works

Genetic abnormalities and pathophysiology of MDS

Hosono, N. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01462-6 · Cited by 108 · see citing works

Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Sun, Y., Meyers, B. A., Czakó, B., Leonard, P. G., Mseeh, F., Harris, A. L., Wu, Q., Johnson, S. B., Parker, C. A., Cross, J. B., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1634 · Cited by 106 · see citing works

SHP-2 Positively Regulates Myogenesis by Coupling to the Rho GTPase Signaling Pathway

Kontaridis, M. I., Eminaga, S., Fornaro, M., Zito, C. I., Sordella, R., Settleman, J. E., & Bennett, A. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.12.5340-5352.2004 · Cited by 104 · see citing works

Functional Effects of PTPN11 (SHP2) Mutations Causing LEOPARD Syndrome on Epidermal Growth Factor-Induced Phosphoinositide 3-Kinase/AKT/Glycogen Synthase Kinase 3β Signaling

Édouard, T., Combier, J., Nédélec, A., Bel-Vialar, S., Metrich, M., Conte-Auriol, F., Lyonnet, S., Parfait, B., Tauber, M., Salles, J., et al. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00646-09 · Cited by 101 · see citing works

Live‐cell imaging of endogenous Ras‐GTP illustrates predominant Ras activation at the plasma membrane

Augsten, M., Pusch, R., Biskup, C., Rennert, K., Wittig, U., Beyer, K., Blume, A., Wetzker, R., Friedrich, K., & Rubio, I. (2006) · EMBO Reports · doi:10.1038/sj.embor.7400560 · Cited by 99 · see citing works

Diverse driving forces underlie the invariant occurrence of the T42A, E139D, I282V and T468M SHP2 amino acid substitutions causing Noonan and LEOPARD syndromes

Martinelli, S., Torreri, P., Tinti, M., Stella, L., Bocchinfuso, G., Flex, E., Grottesi, A., Ceccarini, M., Palleschi, A., Cesareni, G., et al. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn099 · Cited by 97 · see citing works

SHP-2/PTPN11 mediates gliomagenesis driven by PDGFRA and INK4A/ARF aberrations in mice and humans

Liu, K.-W., Feng, H., Bachoo, R. M., Kazlauskas, A., Smith, E. M., Symes, K., Hamilton, R. L., Nagane, M., Nishikawa, R., Hu, B., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43690 · Cited by 92 · see citing works

Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors

Bagdanoff, J. T., Chen, Z., Acker, M., Chen, Y., Chan, H., Dore, M., Firestone, B., Fodor, M., García‐Fortanet, J., Hentemann, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01725 · Cited by 91 · see citing works

Kinetic and Mechanistic Characterization of a Mammalian Protein-tyrosine Phosphatase, PTP1

Zhang, Z. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.19.11199 · Cited by 90 · see citing works

SHP-2 Regulates SOCS-1-mediated Janus Kinase-2 Ubiquitination/Degradation Downstream of the Prolactin Receptor

Ali, S., Nouhi, Z., Chughtai, N., & Ali, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306758200 · Cited by 88 · see citing works

Molecular Basis of Gain-of-Function LEOPARD Syndrome-Associated SHP2 Mutations

Yu, Z.-H., Zhang, R.-Y., Walls, C. D., Chen, L., Zhang, S., Wu, L., Liu, S., & Zhang, Z.-Y. (2014) · Biochemistry · doi:10.1021/bi5002695 · Cited by 87 · see citing works

6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors

Sarver, P., Acker, M., Bagdanoff, J. T., Chen, Z., Chen, Y.-N., Chan, H., Firestone, B., Fodor, M., Fortanet, J., Hao, H., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01726 · Cited by 87 · see citing works

Gain-of-function/Noonan syndrome SHP-2/ Ptpn11 mutants enhance calcium oscillations and impair NFAT signaling

Uhlén, P., Burch, P. M., Zito, C. I., Estrada, M., Ehrlich, B. E., & Bennett, A. M. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510876103 · Cited by 86 · see citing works

Negative regulation of signal transducer and activator of transcription-3 signalling cascade by lupeol inhibits growth and induces apoptosis in hepatocellular carcinoma cells

Siveen, K. S., Nguyen, A. H., Lee, J. H., Li, F., Singh, S. S., Kumar, A. P., Low, G., Jha, S. K., Tergaonkar, V., Ahn, K. S., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.422 · Cited by 85 · see citing works

Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11)

Qiu, W., Wang, X., Romanov, V., Hutchinson, A., Lin, A., Ruzanov, M., Battaile, K. P., PAI, E. F., Neel, B. G., & Chirgadze, N. Y. (2014) · BMC Structural Biology · doi:10.1186/1472-6807-14-10 · Cited by 85 · see citing works

Discovery of thalidomide-based PROTAC small molecules as the highly efficient SHP2 degraders

Yang, X., Wang, Z., Pei, Y., Song, N., Xu, L., Feng, B., Wang, H., Luo, X., Hu, X., Qiu, X., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113341 · Cited by 85 · see citing works

Leptin activates STAT and ERK2 pathways and induces gastric cancer cell proliferation

Pai, R., Lin, C. K., Tran, T., & Tarnawski, A. S. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.03.236 · Cited by 83 · see citing works

Novel PROTACs for degradation of SHP2 protein

Zheng, M., Liu, Y., Wu, C., Yang, K., Wang, Q., Zhou, Y., Chen, L., & Li, H. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104788 · Cited by 81 · see citing works

Therapeutic potential of targeting SHP2 in human developmental disorders and cancers

Shen, D., Chen, W., Zhu, J., Wu, G., Shen, R., Xi, M., & Sun, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112117 · Cited by 78 · see citing works

Anticancer Activity of Sodium Stibogluconate in Synergy with IFNs

Yi, T., Pathak, M. K., Lindner, D. J., Ketterer, M. E., Farver, C. F., & Borden, E. C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5978 · Cited by 70 · see citing works

Targeting a Cryptic Allosteric Site for Selective Inhibition of the Oncogenic Protein Tyrosine Phosphatase Shp2

Chio, C. M., Lim, C. S., & Bishop, A. C. (2014) · Biochemistry · doi:10.1021/bi5013595 · Cited by 65 · see citing works

Shp2 deletion in hepatocytes suppresses hepatocarcinogenesis driven by oncogenic β-Catenin, PIK3CA and MET

Liu, J. J., Li, Y., Chen, W. S., Liang, Y., Wang, G., Zong, M., Kaneko, K., Xu, R., Karin, M., & Feng, G. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.02.014 · Cited by 64 · see citing works

Cytokine signalling via gp130 in gastric cancer

Howlett, M., Menheniott, T. R., Judd, L. M., & Giraud, A. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2009.07.009 · Cited by 62 · see citing works

Inhibition of IFN-γ-Induced STAT1 Tyrosine Phosphorylation by Human CMV Is Mediated by SHP2

Baron, M., & Davignon, J. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.8.5530 · Cited by 61 · see citing works

Strategies to overcome drug resistance using SHP2 inhibitors

Liu, M., Gao, S., Elhassan, R. M., Hou, X., & Fang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.037 · Cited by 59 · see citing works

The protein tyrosine phosphatase, Shp2, positively contributes to FLT3-ITD-induced hematopoietic progenitor hyperproliferation and malignant disease in vivo

Nabinger, S. C., Li, X. J., Ramdas, B., He, Y., Zhang, X., Zeng, L., Richine, B. M., Bowling, J. D., Fukuda, S., Goenka, S., et al. (2012) · Leukemia · doi:10.1038/leu.2012.308 · Cited by 56 · see citing works

Growth hormone modulation of EGF-induced PI3K-Akt pathway in mice liver

Díaz, M. E., González, L., Miquet, J. G., Martinez, C. S., Sotelo, A. I., Bartke, A., & Turyn, D. (2011) · Cellular Signalling · doi:10.1016/j.cellsig.2011.10.001 · Cited by 54 · see citing works

Identification of an allosteric benzothiazolopyrimidone inhibitor of the oncogenic protein tyrosine phosphatase SHP2

LaRochelle, J. R., Fodor, M., Ellegast, J. M., Liu, X., Vemulapalli, V., Mohseni, M., Stams, T., Buhrlage, S. J., Stegmaier, K., LaMarche, M. J., et al. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.025 · Cited by 51 · see citing works

A critical role for SHP2 in STAT5 activation and growth factor–mediated proliferation, survival, and differentiation of human CD34+ cells

Li, L., Modi, H., McDonald, T., Rossi, J., Yee, J., & Bhatia, R. (2011) · Blood · doi:10.1182/blood-2010-06-288910 · Cited by 49 · see citing works

TIGIT, A Novel Therapeutic Target for Tumor Immunotherapy

Liu, X., Hou, M., & Liu, Y. (2016) · Immunological Investigations · doi:10.1080/08820139.2016.1237524 · Cited by 47 · see citing works

Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders

Tang, K., Jia, Y.-N., Yu, B., & Liu, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112657 · Cited by 47 · see citing works

Constitutively Active SHP2 Cooperates with HoxA10 Overexpression to Induce Acute Myeloid Leukemia

Wang, H., Lindsey, S. C., Konieczna, I. M., Bei, L., Horvath, E., Huang, W., Saberwal, G. S., & Eklund, E. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804704200 · Cited by 46 · see citing works

A Cross-Species Study of PI3K Protein-Protein Interactions Reveals the Direct Interaction of P85 and SHP2

Breitkopf, S. B., Yang, X., Begley, M. J., Kulkarni, M. M., Chiu, Y., Turke, A. B., Lauriol, J., Yuan, M., Qi, J., Engelman, J. A., et al. (2016) · Scientific Reports · doi:10.1038/srep20471 · Cited by 45 · see citing works

The Allosteric Site on SHP2’s Protein Tyrosine Phosphatase Domain is Targetable with Druglike Small Molecules

Marsh-Armstrong, B. P., Fajnzylber, J. M., Korntner, S., Plaman, B. A., & Bishop, A. C. (2018) · ACS Omega · doi:10.1021/acsomega.8b02200 · Cited by 44 · see citing works

Regulation of SHP2 by PTEN/AKT/GSK-3β signaling facilitates IFN-γ resistance in hyperproliferating gastric cancer

Tseng, P., Huang, W., Chen, C., Sheu, B., Shan, Y., Tsai, C., Wang, C., Chen, S.-O., Hsieh, C.-Y., & Lin, C. (2012) · Immunobiology · doi:10.1016/j.imbio.2012.01.001 · Cited by 39 · see citing works

Expression and Clinical Significance of SHP2 in Gastric Cancer

Dong, S., Fq, L., Zhang, Q., Lv, K.-Z., Yang, H.-L., Gao, Y., & Yu, J.-R. (2012) · Journal of International Medical Research · doi:10.1177/030006051204000605 · Cited by 39 · see citing works

Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds

Guo, W., & Xu, Q. (2020) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2020.06.002 · Cited by 39 · see citing works

Shipping out MEK inhibitor resistance with SHP2 inhibitors

Torres-Ayuso, P., & Brognard, J. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0915 · Cited by 37 · see citing works

SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells

Liu, Z., Zhao, Y. Q., Fang, J., Cui, R., Xiao, Y., & Xu, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.18591 · Cited by 36 · see citing works

Shp2 Inhibits Proliferation of Esophageal Squamous Cell Cancer via Dephosphorylation of Stat3

Qi, C., Han, T., Tang, H., Huang, K.-N., Min, J., Li, J., Ding, X.-Y., & Xu, Z.-F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18010134 · Cited by 35 · see citing works

Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma

Xu, J., Zeng, L., Shen, W., Turchi, J. J., & Zhang, Z. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.09.028 · Cited by 34 · see citing works

A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors

Song, Y., Zhao, M., Wu, Y., Yu, B., & Liu, H. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.021 · Cited by 34 · see citing works

Shp2 SUMOylation promotes ERK activation and hepatocellular carcinoma development

Deng, R., Zhao, X., Qu, Y., Chen, C., Zhu, C., Zhang, H., Yuan, H., Jin, H. Z., Liu, X., Wang, Y., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3323 · Cited by 32 · see citing works

SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.

Gu, J., Han, T., Ma, R., Zhu, Y.-L., Jia, Y., Du, J.-J., Chen, Y., Jiang, X.-J., Xie, X.-D., & Guo, X. (2014) · International Journal of Oncology · doi:10.3892/ijo.2013.2191 · Cited by 31 · see citing works

Syk kinase and Shp2 phosphatase inhibition cooperate to reduce FLT3-ITD-induced STAT5 activation and proliferation of acute myeloid leukemia

Richine, B. M., Virts, E. L., Bowling, J. D., Ramdas, B., Mali, R. S., Naoye, R., Liu, Z., Zhang, Z.-Y., Boswell, H. S., Kapur, R., et al. (2016) · Leukemia · doi:10.1038/leu.2016.131 · Cited by 26 · see citing works

SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells

Jiang, L., Xu, W., Chen, Y., & Zhang, Y. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1646748 · Cited by 26 · see citing works

Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer

Chen, M., Wang, Y., Wu, D., Chen, C.-Y., & Lee, H. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.01.027 · Cited by 25 · see citing works

The tyrosine phosphatase SHP‐2 regulates differentiation and apoptosis of individual primary T lymphocytes

Hoff, H., & Brunner-Weinzierl, M. C. (2007) · European Journal of Immunology · doi:10.1002/eji.200636240 · Cited by 21 · see citing works

An increase in galectin-3 causes cellular unresponsiveness to IFN-γ-induced signal transduction and growth inhibition in gastric cancer cells

Tseng, P., Chen, C., Shan, Y., & Lin, C. (2016) · Oncotarget · doi:10.18632/oncotarget.7750 · Cited by 21 · see citing works

The prognostic significance of SHP2 and its binding protein Hook1 in non-small cell lung cancer

He, L., Li, Y., Huang, X., Cheng, H., Ke, Y., & Wang, L.-R. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s210223 · Cited by 19 · see citing works

Enhanced anti-melanoma efficacy of interferon alfa-2b via inhibition of Shp2

Win-Piazza, H., Schneeberger, V. E., Chen, L., Pernazza, D., Lawrence, H. R., Sebti, S. M., Lawrence, N. J., & Wu, J. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.01.034 · Cited by 18 · see citing works

Shp2 regulates migratory behavior and response to EGFR-TKIs through ERK1/2 pathway activation in non-small cell lung cancer cells

Sun, Y., Zhuo, Z., Xian, H., Chen, K., Yang, F., & Zhao, X. T. (2017) · Oncotarget · doi:10.18632/oncotarget.20249 · Cited by 18 · see citing works

Emerging chemical scaffolds with potential SHP2 phosphatase inhibitory capabilities – A comprehensive review

Tripathi, R. K. P., & Ayyannan, S. R. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13807 · Cited by 18 · see citing works

Small‐Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview

Mitra, R., & Ayyannan, S. R. (2020) · ChemMedChem · doi:10.1002/cmdc.202000706 · Cited by 17 · see citing works

The second-sphere residue T263 is important for the function and catalytic activity of PTP1B via interaction with the WPD-loop

Xiao, P., Xiao, W., Wang, H., Fu, X.-L., Cui, F., Yu, X., Wen, S.-S., Bi, W., & Sun, J. (2014) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2014.10.004 · Cited by 16 · see citing works

Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798

Yang, X., Tang, C., Luo, H., Wang, H., & Zhou, X. (2017) · Oncotarget · doi:10.18632/oncotarget.15641 · Cited by 16 · see citing works

Gain-Of-Function E76K-Mutant SHP2 Promotes Cell Proliferation, Metastasis, And Tumor Growth In Glioblastoma Through Activation Of The ERK/CREB Pathway

Yang, F., Xu, M., Wang, S., Song, L., Yu, D., Li, Y., Cao, R., Zhang, X., Chen, Z., Zhang, Q., et al. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s222881 · Cited by 16 · see citing works

Shp2 activation in bone marrow microenvironment mediates the drug resistance of B-cell acute lymphoblastic leukemia through enhancing the role of VCAM-1/VLA-4

Yu, K., Yin, Y., Ma, D., Lu, T., Wei, D., Xiong, J., Zhou, Z., Zhang, T., Zhang, S., Fang, Q., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2019.106008 · Cited by 16 · see citing works

Low expression of SHP-2 is associated with less favorable prostate cancer outcomes

Tassidis, H., Brokken, L. J. S., Jirström, K., Bjartell, A. S., Ulmert, D., Härkönen, P. L., & Wingren, A. G. (2012) · Tumor Biology · doi:10.1007/s13277-012-0590-1 · Cited by 14 · see citing works

SHP‐2 phosphatase promotes cervical cancer cell proliferation through inhibiting interferon‐β production

Meng, F., Zhao, X., & Zhang, S. (2012) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2012.01952.x · Cited by 9 · see citing works

Gab2 is Essential for Transformation by FLT3‐ITD in Acute Myeloid Leukemia

Sies, K., Spohr, C., Gründer, A., Todorova, R., Uhl, F. M., Huber, J., Zeiser, R., Pahl, H. L., Becker, H., Aumann, K., et al. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000184 · Cited by 7 · see citing works

Expressions of Src homology 2 domain-containing phosphatase and its clinical significance in laryngeal carcinoma

Dong, L., Li, G. Q., Tian, Z., Wang, Z. M., & Xu, K. (2013) · Genetics and Molecular Research · doi:10.4238/2013.october.7.6 · Cited by 6 · see citing works

An allosteric inhibitor of SHP2 effectively targets PDGFRα-driven glioblastoma

Tannous, B. A., & Badr, C. E. (2019) · Neuro-Oncology · doi:10.1093/neuonc/noz176 · Cited by 6 · see citing works

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works

Small molecule inhibitors targeting the cancers

Liu, G., Chen, T., Zhang, X., Ma, X., & Shi, H. (2022) · MedComm · doi:10.1002/mco2.181 · Cited by 198 · see citing works

Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers

Dillon, M., Lopez, A. R., Lin, E., Sales, D., Perets, R., & Jain, P. (2021) · Cancers · doi:10.3390/cancers13205059 · Cited by 160 · see citing works

Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy

Pan, J., Zhou, L., Zhang, C., Xu, Q., & Sun, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01038-3 · Cited by 115 · see citing works

Strategies Targeting Protein Tyrosine Phosphatase SHP2 for Cancer Therapy

Song, Y., Wang, S., Zhao, M., Yang, X., & Yu, B. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c02008 · Cited by 100 · see citing works

Quercetin as a JAK–STAT inhibitor: a potential role in solid tumors and neurodegenerative diseases

Zalpoor, H., Nabi‐Afjadi, M., Forghaniesfidvajani, R., Tavakol, C., Farahighasreaboonasr, F., Pakizeh, F., Dana, V. G., & Seif, F. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00355-3 · Cited by 76 · see citing works

Immune Checkpoint Receptors Signaling in T Cells

Baldanzi, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073529 · Cited by 71 · see citing works

Discovery of ML210-Based glutathione peroxidase 4 (GPX4) degrader inducing ferroptosis of human cancer cells

Wang, H., Wang, C., Li, B., Zheng, C., Liu, Z., Liu, Z., Zhang, L., & Xu, P. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115343 · Cited by 67 · see citing works

Harnessing the cyclization strategy for new drug discovery

Tang, K., Wang, S., Gao, W., Song, Y., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.022 · Cited by 58 · see citing works

PROTACs: Novel tools for improving immunotherapy in cancer

Li, S., Chen, T., Liu, J., Zhang, H., Li, J., Wang, Z. P., & Shang, G. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216128 · Cited by 52 · see citing works

Crystallographic landscape of SHP2 provides molecular insights for SHP2 targeted drug discovery

Song, Y., Yang, X., Wang, S., Zhao, M., & Yu, B. (2022) · Medicinal Research Reviews · doi:10.1002/med.21890 · Cited by 37 · see citing works

A New View of Activating Mutations in Cancer

Nussinov, R., Tsai, C., & Jang, H. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-2125 · Cited by 35 · see citing works

Application of functional peptides in the electrochemical and optical biosensing of cancer biomarkers

Cao, Y., Zhou, L. Y., Fang, Z., Zou, Z., Zhao, J. T., Zuo, X., & Li, G. (2023) · Chemical Communications · doi:10.1039/d2cc06824a · Cited by 35 · see citing works

PTPN2, A Key Predictor of Prognosis for Pancreatic Adenocarcinoma, Significantly Regulates Cell Cycles, Apoptosis, and Metastasis

Kuang, W., Wang, X., Ding, J., Li, J., Ji, M., Chen, W., Wang, L., & Yang, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.805311 · Cited by 34 · see citing works

Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull’s eye for targeted therapy?

Chen, X., Keller, S. J., Hafner, P., Alrawashdeh, A. Y., Avery, T. Y., Norona, J., Zhou, J., & Ruess, D. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340726 · Cited by 32 · see citing works

Non-Receptor Tyrosine Kinases: Their Structure and Mechanistic Role in Tumor Progression and Resistance

Eshaq, A. M., Flanagan, T. W., Hassan, S.-Y., Asheikh, S. A. A., Al-Amoudi, W. A., Santourlidis, S., Hassan, S.-L., Alamodi, M. O., Bendhack, M. L., Alamodi, M. O., et al. (2024) · Cancers · doi:10.3390/cancers16152754 · Cited by 30 · see citing works

Small-Molecule PROTACs for Cancer Immunotherapy

Liu, Z., Zhang, Y., Xiang, Y., & Kang, X. (2022) · Molecules · doi:10.3390/molecules27175439 · Cited by 29 · see citing works

Overcoming Immune Checkpoint Therapy Resistance with SHP2 Inhibition in Cancer and Immune Cells: A Review of the Literature and Novel Combinatorial Approaches

Tojjari, A., Saeed, A., Sadeghipour, A., Kurzrock, R., & Cavalcante, L. L. (2023) · Cancers · doi:10.3390/cancers15225384 · Cited by 30 · see citing works

Discovery of a Novel Src Homology-2 Domain Containing Protein Tyrosine Phosphatase-2 (SHP2) and Cyclin-Dependent Kinase 4 (CDK4) Dual Inhibitor for the Treatment of Triple-Negative Breast Cancer

Chen, X., Shu, C., Li, W., Hou, Q., Luo, G., Yang, K., & Wu, X. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00063 · Cited by 27 · see citing works

Recent applications of computational methods to allosteric drug discovery

Govindaraj, R. G., Thangapandian, S., Schauperl, M., Denny, R. A., & Diller, D. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.1070328 · Cited by 30 · see citing works

Advances in SHP2 tunnel allosteric inhibitors and bifunctional molecules

Guo, Z., Duan, Y., Sun, K., Zheng, T., Liu, J., Xu, S., & Xu, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116579 · Cited by 25 · see citing works

Targeting phosphatases: From molecule design to clinical trials

Guo, M., Li, Z., Gu, M., Gu, J., You, Q., & Wang, L. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116031 · Cited by 23 · see citing works

Binding Free Energy Calculation Based on the Fragment Molecular Orbital Method and Its Application in Designing Novel SHP-2 Allosteric Inhibitors

Yuan, Z., Chen, X., Fan, S., Chang, L., Chu, L., Zhang, Y., Wang, J., Li, S., Xie, J., Jian-guo, H., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010671 · Cited by 22 · see citing works

Dihydrotanshinone I Inhibits the Proliferation and Growth of Oxaliplatin-Resistant Human HCT116 Colorectal Cancer Cells

Wang, M., Xiang, Y., Wang, R., Zhang, L., Zhang, H., Chen, H., Luan, X., & Chen, L. (2022) · Molecules · doi:10.3390/molecules27227774 · Cited by 21 · see citing works

Structure-based design, synthesis and biological evaluation of aminopyrazines as highly potent, selective, and cellularly active allosteric SHP2 inhibitors

Tang, K., Zhao, M., Wu, Y.-H., Wu, Q., Wang, S., Dong, Y., Yu, B., Song, Y., & Liu, H.-M. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114106 · Cited by 20 · see citing works

PTPN14 promotes gastric cancer progression by PI3KA/AKT/mTOR pathway

Li, H., Guan, B., Liu, S., Liu, H., Song, L., Zhang, G., Zhao, R., Zhou, C., & Gao, P. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05712-4 · Cited by 18 · see citing works

Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions

Zhong, J., Bai, H., Wang, Z., Duan, J., Zhuang, W., Wang, D., Wan, R., Xu, J., Fei, K., Ma, Z., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-022-0976-4 · Cited by 18 · see citing works

Small-molecule Modulators Targeting SHP2 for Cancer Therapy

Chen, Y., Mi, D., & Li, Y. (2022) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520622666220921093052 · Cited by 16 · see citing works

The efficacy and safety of PI3K and AKT inhibitors for patients with cancer: A systematic review and network meta-analysis

Zhang, Y., Xu, X., Yang, K., Wang, S., Zhang, T., Hui, F., Zheng, F., Geng, H., Xu, C., Xun, F., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176952 · Cited by 15 · see citing works

A pan-cancer analysis confirms PTPN11’s potential as a prognostic and immunological biomarker

Cao, Y., Duan, H., Su, A., Xu, L., & Lai, B. (2022) · Aging · doi:10.18632/aging.204171 · Cited by 15 · see citing works

Targeting undruggable phosphatase overcomes trastuzumab resistance by inhibiting multi-oncogenic kinases

Wang, L., Lin, Y., Yao, Z., Babu, N., Lin, W., Chen, C., Du, L., Cai, S., Pan, Y., Xiong, X., et al. (2024) · Drug Resistance Updates · doi:10.1016/j.drup.2024.101118 · Cited by 14 · see citing works

Design, Synthesis and Antitumor Activity of a Novel Class of SHP2 Allosteric Inhibitors with a Furanyl Amide-Based Scaffold

Zhu, C., Zhao, H., Yang, W., Chen, K., Liu, X., Yu, Y., Li, R., Tan, R., & Yu, Z. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01217 · Cited by 14 · see citing works

DeepPath: overcoming data scarcity for protein transition pathway prediction using physics-based deep learning

Pang, Y. T., Yang, L., Kuo, K. M., & Gumbart, J. C. (2026) · Chemical Science · doi:10.1039/d5sc08253f · Cited by 13 · see citing works

Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor

Tang, K., Wang, S., Feng, S., Yang, X., Guo, Y., Ren, X., Bai, L., Yu, B., Liu, H., & Song, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.028 · Cited by 12 · see citing works

A comprehensive overview of the molecular features and therapeutic targets in BRAF V600E ‐mutant colorectal cancer

Gu, R., Fang, H., Wang, R., Dai, W., & Cai, G. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1764 · Cited by 12 · see citing works

Ferroptosis triggers anti-tumor immunity via promoting chaperone-mediated autophagic degradation of SHP2

Zhu, J., Li, X., Chen, W., Zuo, Z., Gong, Q., Hu, J., Huang, K., Liu, W., Gu, Y., Xu, Q., et al. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103796 · Cited by 12 · see citing works

Interactions between modified fullerenes and proteins in cancer nanotechnology

Serda, M., Korzuch, J., Dreszer, D., Krzykawska-Serda, M., & Musioł, R. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103704 · Cited by 12 · see citing works

Therapeutic efficacy of the novel SHP2 degrader SHP2-D26, alone or in combination, against lung cancer is associated with modulation of p70S6K/S6, Bim and Mcl-1

Deng, Y., Ma, G., Vallega, K. A., Wang, D., Wang, M., Wang, C., Wang, S., Ramalingam, S. S., & Sun, S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-022-00472-3 · Cited by 12 · see citing works

Tyrosine phosphatase SHP2 aggravates tumor progression and glycolysis by dephosphorylating PKM2 in gastric cancer

Wang, P., Han, Y., Pan, W., Du, J., Zuo, D., Ba, Y., & Zhang, H. (2024) · MedComm · doi:10.1002/mco2.527 · Cited by 11 · see citing works

Protein tyrosine phosphatase receptor type kappa (PTPRK) revisited: evolving insights into structure, function, and pathology

Chen, Z., Liu, T., Wang, A. Q., Chen, X., Zhang, R., Wang, X. C., Lv, C. Y., Pan, R. L., Wang, O. C., & Lu, X. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06496-1 · Cited by 11 · see citing works

Cathepsin K inhibition induces Raptor destabilization and mitochondrial dysfunction via Syk/SHP2/Src/OTUB1 axis-mediated signaling

Seo, S. U., Woo, S. M., & Kwon, T. K. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05884-z · Cited by 11 · see citing works

Protein Tyrosine Phosphatase Receptor-type Q: Structure, Activity, and Implications in Human Disease

Zhang, W., Tang, Z., Fan, S., Yao, D., Zhang, Z., Guan, C., Deng, W., & Ying, Y. (2022) · Protein and Peptide Letters · doi:10.2174/0929866529666220511141826 · Cited by 10 · see citing works

Combining EGFR Inhibitors With SHP2 Or LSD1 Inhibitors to Overcome Multidrug Resistance in Cancer

Zhang, H., Yang, X., Song, Y., & Yu, B. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0326 · Cited by 10 · see citing works

sPGGM: a sample-perturbed Gaussian graphical model for identifying pre-disease stages and signaling molecules of disease progression

Zhong, J., Li, J., Gu, X., Ding, D., Ling, F., Chen, P., & Liu, R. (2025) · National Science Review · doi:10.1093/nsr/nwaf189 · Cited by 9 · see citing works

Targeting SHP2: Dual breakthroughs in colorectal cancer therapy–from signaling pathway modulation to immune microenvironment remodeling

Liu, P., & Chen, J. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i7.107380 · Cited by 9 · see citing works

Setting sail: Maneuvering SHP2 activity and its effects in cancer

Welsh, C. L., Allen, S., & Madan, L. K. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.03.003 · Cited by 8 · see citing works

SH2db, an information system for the SH2 domain

Bajusz, D., Pándy‐Szekeres, G., Takács, Á., de Araujo, E. D., & Keserű, G. M. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad420 · Cited by 8 · see citing works

WWP1 inhibition increases SHP2 inhibitor efficacy in colorectal cancer

Fan, H., Hu, X., Cao, F., Zhou, L., Wen, R., Shen, H., Fu, Y., Zhu, X., Jia, H., Liu, Z., et al. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00650-6 · Cited by 9 · see citing works

Allosteric SHP2 inhibition enhances regorafenib's effectiveness in colorectal cancer treatment

Han, X., Wang, W., Wang, R., Zhang, W., Zhu, L., Xu, Q., Guo, W., & Gu, Y. (2024) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2024.149812 · Cited by 7 · see citing works

Therapeutic potential of targeting protein tyrosine phosphatases in liver diseases

Wang, A., Zhang, Y., Lv, X., & Liang, G. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.05.006 · Cited by 7 · see citing works

Toward a Treatment of Cancer: Design and In Vitro/In Vivo Evaluation of Uncharged Pyrazoline Derivatives as a Series of Novel SHP2 Inhibitors

Dai, J., Zhang, Y., Gao, Y., Bai, X., Liu, F., Li, S., Yu, Y., Hu, W., Shi, T., Shi, D., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073497 · Cited by 7 · see citing works

Enhancing KRAS G12D inhibitor sensitivity in pancreatic cancer through SHP2/PI3K pathway

Hao, M.-W., Zhang, T., Dong, D. F., Xin Min, Z. H. O. U., & Gao, H. (2025) · Medical Oncology · doi:10.1007/s12032-025-02683-8 · Cited by 6 · see citing works

Allosteric SHP2 inhibitors suppress lung cancer cell migration by inhibiting non-canonical activation of EphA2 via the ERK-RSK signaling pathway

Nguyen, K., Zhou, Y., Yokoyama, S., Sasaki, S., Yano, S., Hayashi, R., Koizumi, K., Hayakawa, Y., & Sakurai, H. (2025) · Scientific Reports · doi:10.1038/s41598-025-20770-8 · Cited by 6 · see citing works

Phosphatase Dysregulation in Cancer: Signaling Pathways and Therapeutic Opportunities

Jama, M., Overduin, M., & Barakat, K. (2025) · MedComm – Oncology · doi:10.1002/mog2.70028 · Cited by 7 · see citing works

SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma

Zhou, P., Xiao, M., Li, W., Sun, X., Bai, Y., Meng, F., Zhu, Z., Yuan, W., & Sun, K. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.841308 · Cited by 6 · see citing works

Discovery of a novel SHP2 allosteric inhibitor using virtual screening, FMO calculation, and molecular dynamic simulation

Yuan, Z., Zhang, M., Chang, L., Chen, X., Ruan, S., Shi, S., Zhang, Y., Zhu, L., Li, H., & Li, S. (2024) · Journal of Molecular Modeling · doi:10.1007/s00894-024-05935-y · Cited by 6 · see citing works

Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets

Nunes‐Xavier, C. E., Zaldumbide, L., Mosteiro, L., Almaraz, R. L., de Andoín, N. G., Aguirre, P., Emaldi, M., Torices, L., Lopez, J. I., & Pulido, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.811297 · Cited by 6 · see citing works

KRAS Q61H Mutation Confers Cancer Cells with Acquired Resistance to SHP2 Inhibition

Song, Y., Yang, X., & Yu, B. (2022) · Pharmaceutical Fronts · doi:10.1055/s-0042-1743411 · Cited by 6 · see citing works

Synthesis, fluorescence properties of novel thiazolo[3,2-b][1,2,4]triazol derivatives as potent SHP2 inhibitors and its uses in sensing for Fe3+ and cell imaging

Yan, X. F., Zhang, C., Gao, L., Cao, Z.-T., Gan, S., Li, J. X., Xiang, D.-J., Zhou, Y., & Wang, W. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140960 · Cited by 5 · see citing works

Shp-1 regulates the activity of low-affinity T cells specific to endogenous self-antigen during melanoma tumor growth and drives resistance to immune checkpoint inhibition

Matous, J. G., Snook, J. P., Contreras, N. A., Ramstead, A. G., Charley, K. R., Kolawole, E. M., Kisiolek, J. N., Flint, K. A., Soedel, A. J., Robinson, B., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010879 · Cited by 5 · see citing works

Identification of new small molecule allosteric SHP2 inhibitor through pharmacophore-based virtual screening, molecular docking, molecular dynamics simulation studies, synthesis and in vitro evaluation

Mitra, R., Kumar, S., & Ayyannan, S. R. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2291733 · Cited by 5 · see citing works

Optimization of SHP2 allosteric inhibitors with novel tail heterocycles and their potential as antitumor therapeutics

Zhu, C., Li, L., Yu, Y., Wang, X., Shi, Y., Gao, Y., Chen, K., Liu, X., Cui, Y., Zhang, T., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117078 · Cited by 5 · see citing works

Targeting SHP2 with Natural Products: Exploring Saponin-Based Allosteric Inhibitors and Their Therapeutic Potential

Moon, D. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050309 · Cited by 4 · see citing works

Pepsinogen C Interacts with IQGAP1 to Inhibit the Metastasis of Gastric Cancer Cells by Suppressing Rho-GTPase Pathway

Ding, H.-X., Liu, Y., Lü, X., Liu, A., Xu, Q., & Yuan, Y. (2024) · Cancers · doi:10.3390/cancers16101796 · Cited by 4 · see citing works

Dynamic responses during early development of the sea urchin Strongylocentrotus intermedius to CO2-driven ocean acidification: A microRNA-mRNA integrated analysis

Yin, W., Mai, W., Cui, D., Zhao, T., Song, J., Zhang, W., Chang, Y., & Zhan, Y. (2025) · Marine Pollution Bulletin · doi:10.1016/j.marpolbul.2024.117514 · Cited by 4 · see citing works

SHP2 is a multifunctional target in anaplastic thyroid carcinoma: Cell intrinsic and immune-dependent anti-tumor effects

Marotta, M., Zirpoli, S., Prevete, N., Simone, C. D., Cristofano, A. D., Liotti, F., & Melillo, R. M. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118384 · Cited by 4 · see citing works

Deletion of the tyrosine phosphatase Shp2 in cervical cancer cells promotes reprogramming of glutamine metabolism

Gao, X., Kang, J., Li, X., Chen, C., & Luo, D. (2023) · The FASEB Journal · doi:10.1096/fj.202202078rr · Cited by 4 · see citing works

High expression of SHP2 predicts a promising prognosis in colorectal cancer

Liu, X., Li, M., Chen, L., Wen, F., Zheng, S. S., & Ge, W. (2023) · Indian Journal of Pathology and Microbiology · doi:10.4103/ijpm.ijpm_894_22 · Cited by 4 · see citing works

New indole-diterpenoids with protein tyrosine phosphatase inhibitory activity from a marine-derived fungus Penicillium janthinellum

Li, L., Qin, X.-X., Qin, Y., Wang, T., Liu, X.-M., Wang, X., Liu, Z., You, Z., & Cao, F. (2024) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2024.140428 · Cited by 4 · see citing works

SHP2 inhibition and adjuvant therapy synergistically target KIT‐mutant GISTs via ERK1/2‐regulated GSK3β/cyclin D1 pathway

He, C., Yu, J., Mao, S., Yang, S., Jiang, X., Huang, L., Li, M., He, Y., Zhang, X., & Xiang, X. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70231 · Cited by 4 · see citing works

Cheminformatic profiling of Azardirachta indica phytochemicals as dual SHP2/HSP90 oncogenic inhibitors: Identification of nimbocinol, nimbidinin, and margolone

Agboola, O. E., Ayinla, Z. A., Apalowo, O. E., Agboola, S. S., Fajana, O. M., Ekundayo, B. E., Itakorode, B. O., & Oyinloye, B. E. (2025) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2025.04.001 · Cited by 4 · see citing works

Molecular recognition of ITIM/ITSM domains with SHP2 and their allosteric effect

Yan, C., Ouyang, W., Liu, L., Tang, L., Zhang, Z., Yue, X., Liang, L., Hu, J., & Luo, T. L. (2023) · Physical Chemistry Chemical Physics · doi:10.1039/d3cp03923d · Cited by 4 · see citing works

Emerging Therapeutic Approaches of SHP2-Targeted Modulators

Yang, X., Xiong, J., Yu, B., & Song, Y. (2024) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0348 · Cited by 4 · see citing works

Study on SHP2 Conformational Transition and Structural Characterization of Its High-Potency Allosteric Inhibitors by Molecular Dynamics Simulations Combined with Machine Learning

Wujieti, B., Hao, M., Liu, E., Zhou, L., Wang, H., Zhang, Y., Cui, W., & Chen, B. (2024) · Molecules · doi:10.3390/molecules30010014 · Cited by 3 · see citing works

Comprehensive multi-omics analysis reveals the prognostic and immune regulatory characteristics of the PTPN family in osteosarcoma

Long, C., Ma, B., Zhong, X., Zou, M., Li, K., & Liu, S. (2025) · PLoS ONE · doi:10.1371/journal.pone.0326872 · Cited by 3 · see citing works

Destabilization of the SHP2 and SHP1 protein tyrosine phosphatase domains by a non-conserved “backdoor” cysteine

Yarnall, M. T. N., Kim, S., Korntner, S., & Bishop, A. C. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101370 · Cited by 3 · see citing works

Mometasone Furoate Inhibits the Progression of Head and Neck Squamous Cell Carcinoma via Regulating Protein Tyrosine Phosphatase Non-Receptor Type 11

Qiu, L., Gao, Q., Tao, A., Jiang, J., & Li, C. (2023) · Biomedicines · doi:10.3390/biomedicines11102597 · Cited by 3 · see citing works

SHP2 inhibition reduces somatotroph tumor growth in a pre-clinical model

Barberá, F. G., Picech, F., Cecenarro, L. A., Mezger, G. F., Faure, E. E., Zlocowski, N., Calafat, P., Battista, J. C. D., Mukdsi, J. H., Sosa, L. D. V., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf057 · Cited by 2 · see citing works

Structure-Guided Design of Pyrazolopyrimidinones as Highly Potent and Selective Allosteric SHP2 Inhibitors

Song, Y., Ren, X., Yang, X., Xiong, J., Wang, W., Tang, K., & Yu, B. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00524 · Cited by 2 · see citing works

SHP2-targeted cancer therapeutics: Structural insights, inhibitor development and emerging modalities

Zhang, Y., Zhu, C., Si, C., Lin, Y., Guo, Q., Zhou, H., & Yu, Z. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118708 · Cited by 2 · see citing works

Targeting Protein Phosphatases for the Treatment of Chronic Liver Disease

Li, Y., He, H., & Zhang, N. (2024) · Current Drug Targets · doi:10.2174/0113894501278886231221092522 · Cited by 2 · see citing works

Targeting KRAS and SHP2 signaling pathways for immunomodulation and improving treatment outcomes in solid tumors

Sahu, P., Mitra, A., & Ganguly, A. (2024) · International review of cytology · doi:10.1016/bs.ircmb.2024.01.005 · Cited by 2 · see citing works

Design, Synthesis and Evaluation of Thioacetamide‐Tethered Thiadiazole‐1,2,4‐Triazole Hybrids as SHP2 Inhibitors for Cancer Therapy

Mitra, R., Kumar, S., Chaudhuri, A., Agrawal, A. K., & Ayyannan, S. R. (2024) · ChemistrySelect · doi:10.1002/slct.202401602 · Cited by 2 · see citing works

SHP2 promotes the epithelial-mesenchymal transition in triple negative breast cancer cells by regulating β-catenin

Qian, S., Zhu, J., Han, Q., Cheng, H., & Zhou, H. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06097-x · Cited by 2 · see citing works

Inhibiting the Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Cascade in Cancer and the Heart: for Better or Worse, in Sickness and Health?

Clerk, A., Amadi, S. U., Smith, S. J., & Sugden, P. H. (2024) · International Journal of Drug Discovery and Pharmacology · doi:10.53941/ijddp.2024.100006 · Cited by 2 · see citing works

Discovery of 1H-pyrazolo[3,4- b ]pyrazine derivatives as selective allosteric inhibitor of protein tyrosine phosphatase SHP2 for the treatment of KRAS G12C -mutant non-small cell lung cancer

Xu, W.-Q., Qi, S., Zhao, J., Li, L., Ding, C., & Liu, W. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2308771 · Cited by 1 · see citing works

Lycii Radicis Cortex suppresses the growth of non-small cell lung cancer via enhancing the anti-tumor immunity

Yin, H., Liu, M., Zhao, Y., Wu, H., Zheng, D., Guo, Z., Zhou, Y., Wu, S., Chen, C., Zhang, L., et al. (2024) · Food Science and Human Wellness · doi:10.26599/fshw.2024.9250041 · Cited by 1 · see citing works

Design and Synthesis of S ‐Acetophenylhydrazones of 5‐Methyl‐1,3,4‐Thiadiazole‐2‐Thiol as SHP2 Inhibitory Agents

Mitra, R., Kumar, S., Chaudhuri, A., Majumdar, S., Krishnamurthy, S., Agrawal, A. K., & Ayyannan, S. R. (2025) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402997 · Cited by 1 · see citing works

Dual-specificity phosphatases: Potential targets for cognitive impairment induced by chronic kidney disease

Liao, L., Hu, Q., Zhang, Y., Liao, J., Su, H.-W., Wu, A., Xu, T., & Wu, J. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114883 · Cited by 1 · see citing works

Structure-guided expansion strategy unveils potent allosteric SHP2 inhibitors with synergistic efficacy against AML through MCL-1 co-targeting

Zhang, M., Wu, S., Liu, M., Li, H., Wang, L., Duan, F., Han, R., Shan, C., Jiang, Z., Liao, J., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117988 · Cited by 1 · see citing works

PZR: Advances in research from cellular signaling Hub to emerging therapeutic targets

Wang, H. P., Sha, W., Fu, Y., & Wang, H. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.112061 · Cited by 1 · see citing works

Small-molecule drug discovery in malignant melanoma: current status and prospective developments

Miao, X., Liu, Y., Li, C., Wu, J., Li, Y., Li, Z., Li, J., Sun, Y., & Han, J. (2025) · Medicinal Chemistry Research · doi:10.1007/s00044-025-03515-0 · Cited by 1 · see citing works

Targeting PTPN22 at Nonorthosteric Binding Sites─A Fragment Approach

Lello, P. D., Wells, M. M., Davis, B. J., Daniels, Z., Garner, T. P., Gazzard, L. J., Harris, R., Hubbard, R. E., Landry, M. L., Martin, B. T., et al. (2026) · ACS Omega · doi:10.1021/acsomega.5c11028 · Cited by 1 · see citing works

Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in FGFR2-amplified gastric cancer

Zhang, Y., Wang, H., Wei, Y., Pan, Y., Song, X., Shao, J., Yu, L., Shi, T., & Wang, Y. (2026) · eLife · doi:10.7554/elife.104060.3 · Cited by 1 · see citing works

Targeting SHP2 for Cancer Treatment: Advances and Prospects

Song, Y., & Yu, B. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_256-1 · Cited by 1 · see citing works

Discovery of Environment-Sensitive Near Infrared SHP2-Targeting Fluorescent Ligands for Living Cells and Tissue Section Imaging

Liang, D., Chen, Y., Yan, L., Guo, C., Zhang, Y., Chen, S., Du, L., Liu, A., Sun, D., Li, M., et al. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c00591 · Cited by 1 · see citing works

Novel Pyrazolopyrazine Compounds as SHP2 Inhibitors for Treating Glioblastoma

Sabnis, R. W. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00393 · Cited by 1 · see citing works

High expression of SHP2 predicts a promising prognosis in colorectal cancerPreprint

Liu, X., Li, M., Chen, L., Wen, F., Zheng, S. S., & Ge, W. (2022) · Research Square · doi:10.21203/rs.3.rs-1717423/v1

Research Progress in Allosteric SHP2 Inhibitors

堵, 桐. (2022) · Hans Journal of Medicinal Chemistry · doi:10.12677/hjmce.2022.102021

Exploring Allosteric Inhibitors of Protein Tyrosine Phosphatases Through High-Throughput Screening

Hayashi, T., & Hatakeyama, M. (2023) · Methods in molecular biology · doi:10.1007/978-1-0716-3331-1_18

Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy

Scheiter, A., Lu, L., Gao, L. H., & Feng, G. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-013740 · Cited by 11 · see citing works

A comprehensive review of SHP2 and its role in cancer

Asmamaw, M. D., Shi, X.-J., Zhang, L.-R., & Liu, H.-M. (2022) · Cellular Oncology · doi:10.1007/s13402-022-00698-1 · Cited by 119 · see citing works

Setting sail: Maneuvering SHP2 activity and its effects in cancer

Welsh, C. L., Allen, S., & Madan, L. K. (2023) · Advances in cancer research · doi:10.1016/bs.acr.2023.03.003 · Cited by 8 · see citing works

SHP2-targeted cancer therapeutics: Structural insights, inhibitor development and emerging modalities

Zhang, Y., Zhu, C., Si, C., Lin, Y., Guo, Q., Zhou, H., & Yu, Z. (2026) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2026.118708 · Cited by 2 · see citing works

Protein Tyrosine Phosphatase SHP-2 as Drug Target

Somani, R. R., Madan, D., & Rai, P. (2016) · Mini-Reviews in Organic Chemistry · doi:10.2174/1570193x13666161017141804 · Cited by 2 · see citing works